In this article16 sections
Eli Lilly's once-daily GLP-1 pill, sold as Foundayo. It is a small molecule, not a peptide, so it survives digestion and has no food or water rules. Licensed in the UK since August 2026; average weight loss on the top trial arm was 12.4% over 72 weeks.
Orforglipron is the first weight-loss pill of its kind. Sold by Eli Lilly as Foundayo, it switches on the same receptor as Wegovy and Mounjaro, but it is not a peptide at all: it is a small chemical that survives the stomach, so the tablet comes with no food or water rules. The US FDA approved it in April 2026 and the UK's MHRA authorised it on 10 August 2026. In its main trial, people on the top arm lost 12.4% of their body weight on average over 72 weeks, less than with the leading injections. This is an account of published research, not medical advice.
- Orforglipron (development code LY3502970) was discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018. Lilly sells it as Foundayo.
- It is a small-molecule (non-peptide) GLP-1 receptor agonist, about a fifth of the molecular size of semaglutide, and is absorbed from the gut like an ordinary tablet.
- The US FDA approved Foundayo for chronic weight management on 1 April 2026; the MHRA authorised it on 10 August 2026, the first approval in Europe.
- In ATTAIN-1 (3,127 adults without diabetes, 72 weeks, NEJM 2025), the 36 mg arm lost 12.4% of body weight against 0.9% on placebo; counting everyone randomised, 11.2% against 2.1%.
- In ATTAIN-MAINTAIN, people switched from Wegovy injections to orforglipron kept all but 0.9 kg of their earlier weight loss over 52 weeks.
- The most common side effects in trials were nausea, constipation, diarrhoea and vomiting; 10.3% on the top ATTAIN-1 arm stopped because of side effects, against 2.7% on placebo.
- In the UK it is a prescription-only medicine, not yet available on the NHS while NICE completes its appraisal.
- ALTA PEPTIDES does not stock orforglipron; it is a licensed medicine supplied only by pharmacies against a prescription.
What is orforglipron?
In shortLilly's once-daily GLP-1 pill, sold as Foundayo, and the first that isn't a peptide.
Eli Lilly; discovered by Chugai, licensed 2018.
Not a peptide. Code LY3502970.
Label: any time, no food or water rules.
MHRA, 10 August 2026. Not yet on the NHS.
Lilly press releases 2025 to 2026; MHRA, 10 August 2026.
Orforglipron (development code LY3502970) is a GLP-1 receptor agonist: a drug that copies the action of GLP-1, a gut hormone released after meals that makes you feel full and helps control blood sugar. Unlike every GLP-1 medicine before it, it is a small synthetic molecule rather than a peptide. It was discovered by the Japanese company Chugai Pharmaceutical and licensed by Eli Lilly in 2018.
Lilly sells the orforglipron pill as Foundayo, once daily, and its label allows it to be taken at any time of day without food or water restrictions. It is licensed for weight management and, in the UK, type 2 diabetes. It acts on one receptor only, GLP-1, like semaglutide rather than the newer multi-hormone drugs. Our GLP-1 receptor agonists explainer maps the whole family.
Why does it matter that orforglipron is a pill, not a peptide?
In shortPeptides get digested; this small molecule doesn't, so there are no fasting rules.
| Peptide GLP-1 drugs | Orforglipron | |
|---|---|---|
| Examples | Semaglutide, tirzepatide, retatrutide | Orforglipron only (approved) |
| Size | Around 4,100 daltons (semaglutide) | About 883 daltons |
| Survives digestion | No, broken down like food | Yes |
| As a tablet | Oral semaglutide only, with absorption enhancer and fasting rules | No fasting rules on the label |
| How it is made | Peptide synthesis or biotech | Standard chemical synthesis |
ClaimAll GLP-1 pills are the same drug as the injections.Tap to check
The Wegovy pill is semaglutide, the same peptide as the injection. Orforglipron is a different, non-peptide molecule that acts on the same receptor.
ClaimA pill works as well as an injection.Tap to check
Counting everyone who started, orforglipron gave 11.2% at 72 weeks and the Wegovy pill 13.6% at 64 weeks, against 20.9% for tirzepatide and 25.0% for retatrutide injections in their trials.
ClaimOrforglipron has no food rules.Tap to check
Its label allows any time of day without food or water restrictions, because it is absorbed like an ordinary small-molecule tablet. Oral semaglutide must be taken fasting.
ClaimBeing a pill means fewer side effects.Tap to check
Digestive side effects were similar to injectable GLP-1 drugs: in ATTAIN-1, 33.7% had nausea on the top arm against 10.4% on placebo.
ClaimA small molecule can be sold as a research chemical instead.Tap to check
Orforglipron is a licensed prescription medicine in the UK. It can only be supplied by a pharmacy against a prescription.
Molecular sizes from published structures; trial figures from ATTAIN-1, OASIS 4, SURMOUNT-1 and TRIUMPH-1. Tap a claim to check it.
Peptides are short chains of amino acids, and the gut is built to digest them. That is why semaglutide, tirzepatide and retatrutide are injected. The one peptide GLP-1 tablet, oral semaglutide (Rybelsus, and now the Wegovy pill), needs an absorption enhancer and an empty stomach, and only around 1% of the swallowed peptide reaches the blood.
Orforglipron sidesteps this. At about 883 daltons it is roughly a fifth the size of semaglutide, and it is absorbed like an ordinary tablet, so there are no fasting rules. Small molecules are made by standard chemical synthesis in ordinary tablet plants, which Lilly argues makes it easier to supply at global scale. Our guide to what peptides are explains why chain length matters so much.
How does orforglipron work?
In shortIt switches on the GLP-1 receptor, which cuts appetite and helps insulin.
- 01Swallowed
A small molecule, so it is absorbed from the gut intact.
- 02Binds GLP-1R
Fits a pocket high in the receptor, not the peptide's binding mode.
- 03cAMP signal
Favours the cAMP route; little beta-arrestin recruitment.
- 04Brain and gut
Fuller sooner, fewer cravings, slower stomach emptying.
- 05Pancreas
More insulin when blood sugar is high.
MHRA, 10 August 2026; Kawai et al., PNAS 2020. Half-life 29 to 49 hours in phase 1 (Lilly).
It binds the GLP-1 receptor, the same lock that natural GLP-1 and semaglutide open, although it fits into the lock in a different place (the detail is further down). The switched-on receptor then sends the familiar signals: fullness in the brain's appetite centres, slower stomach emptying, and more insulin when blood sugar is high. The MHRA says it helps people feel fuller for longer and reduces food cravings. Lilly's phase 1 studies measured a half-life of roughly 29 to 49 hours, which suits a once-daily tablet.
What did the orforglipron trials show?
In short12.4% average weight loss at 72 weeks on the top arm, and it held weight off after injections.
Average body-weight loss. Lilly, 16 September 2025; Wharton et al., NEJM 2025. 3,127 adults without diabetes.
Average over 52 weeks on orforglipron.
Average over 52 weeks on orforglipron.
Both groups, before rescue therapy.
Lilly, 18 December 2025. 376 adults from SURMOUNT-5.
ATTAIN-1, published in the New England Journal of Medicine in September 2025, randomised 3,127 adults with obesity or overweight and no diabetes to one of three orforglipron arms (6, 12 or 36 mg) or placebo for 72 weeks. On the top arm, average weight loss was 12.4% against 0.9% on placebo, counting people who stayed on treatment. Counting everyone who started, the orforglipron results were 11.2% against 2.1%.
On that top arm, 59.6% lost at least 10% of their weight and 39.6% at least 15%. Waist size fell by 11.1 cm, and triglycerides and blood pressure improved.
ATTAIN-2, in 1,613 adults with obesity and type 2 diabetes, reported 10.5% orforglipron weight loss at 72 weeks on the top arm against 2.2% on placebo, with HbA1c falling 1.3 to 1.8 points across the arms.
ATTAIN-MAINTAIN asked a different question: can a pill hold weight off after injections? It re-randomised 376 people who had already lost weight on Wegovy or Zepbound (tirzepatide) in the SURMOUNT-5 trial to orforglipron or placebo for 52 weeks. Those switched from Wegovy kept all but 0.9 kg of their earlier loss on average; those switched from Zepbound regained 5.0 kg. At 24 weeks, people moved to placebo had already regained about 9 kg.
What are the side effects of orforglipron?
In shortNausea, constipation, diarrhoea and vomiting, like injectable GLP-1 drugs.
| Orforglipron 36 mg | Placebo | |
|---|---|---|
| Nausea | 33.7% | 10.4% |
| Constipation | 25.4% | 9.3% |
| Vomiting | 24.0% | 3.5% |
| Diarrhoea | 23.1% | 9.6% |
| Stopped due to side effects | 10.3% | 2.7% |
| Liver safety signal | None reported | None |
Lilly, 16 September 2025. Mostly mild to moderate, most common during step-up.
The same kind as injectable GLP-1 drugs: mainly digestive and mostly mild to moderate. In ATTAIN-1, on the 36 mg arm, nausea affected 33.7% (10.4% on placebo), constipation 25.4% (9.3%), diarrhoea 23.1% (9.6%) and vomiting 24.0% (3.5%). Side effects led 10.3% of people on the top arm to stop, against 2.7% on placebo.
Lilly reported no liver safety signal across its trials. That matters because an earlier small-molecule GLP-1 candidate, Pfizer's danuglipron, was dropped in April 2025 after a possible case of drug-induced liver injury. The MHRA lists nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain as the most common orforglipron side effects, and the US label carries the same thyroid tumour warning as other GLP-1 drugs.
Is orforglipron approved in the UK?
In shortYes, since 10 August 2026, on private prescription. Not yet on the NHS.
- 2018Lilly licenses it
Discovered by Chugai Pharmaceutical.
- Sep 2025ATTAIN-1 published
12.4% weight loss at 72 weeks, NEJM.
- Dec 2025ATTAIN-MAINTAIN
Weight held after switching from injections; US filing made.
- 1 Apr 2026FDA approval
Foundayo, under a national priority voucher.
- 10 Aug 2026MHRA authorisation
First in Europe; obesity and type 2 diabetes.
- 27 Jan 2027NICE guidance expected
Needed before any NHS use.
Lilly; MHRA; pharmaphorum, 11 August 2026. Private UK prices about £99 to £199 a month (Medino, August 2026).
Yes. The MHRA authorised orforglipron on 10 August 2026, making the UK the first country in Europe to approve it, for weight management and type 2 diabetes; the US FDA had approved it on 1 April 2026. The Foundayo UK licence makes it prescription-only: only a registered pharmacy can supply it, and the MHRA warns that buying GLP-1 medicines from unregulated sellers carries serious health risks.
Orforglipron UK supply is private for now: it is not on the NHS while NICE completes its appraisal, with its guidance expected to be published on 27 January 2027. Lilly has not published an official Foundayo price for the UK; Medino's comparison of online pharmacies in late August 2026 found roughly £99 to £199 a month, depending on strength. Our guide to UK peptide law explains how licensed medicines differ from research chemicals.
Orforglipron vs the Wegovy pill: which oral GLP-1 is which?
In shortThe Wegovy pill gave a bit more weight loss; orforglipron has no food rules.
| Wegovy pill | Foundayo | |
|---|---|---|
| Drug | Oral semaglutide (peptide) | Orforglipron (small molecule) |
| Maker | Novo Nordisk | Eli Lilly |
| MHRA authorised | 11 June 2026 | 10 August 2026 |
| Label food rules | Empty stomach, wait before food | None |
| Weight loss, all starters | 13.6% at 64 weeks (OASIS 4) | 11.2% at 72 weeks (ATTAIN-1) |
| Heart outcomes data | Proven for semaglutide | Trial under way |
| Type 2 diabetes licence (UK) | Weight only for Wegovy pill | Yes |
MHRA; Novo Nordisk; Lilly. Separate trials, not head-to-head.
There are now two GLP-1 weight-loss pills in the UK. The Wegovy pill is oral semaglutide, a peptide in a tablet; the MHRA authorised it for weight management on 11 June 2026, after FDA approval in December 2025. Foundayo is orforglipron, a small molecule GLP-1 drug with no peptide in it.
On weight, the Wegovy pill looks stronger. In OASIS 4 its 25 mg arm gave 13.6% weight loss at 64 weeks against 2.2% on placebo, counting everyone who started; the comparable orforglipron figure is 11.2% at 72 weeks. The trials were separate, so this is not a head-to-head result. Professor Naveed Sattar of the University of Glasgow has said oral semaglutide appears to give somewhat more weight loss and has proven heart benefits, while orforglipron is simpler: the oral semaglutide label requires an empty stomach and a wait before food, and the orforglipron label does not.
In type 2 diabetes the two have met directly: in ACHIEVE-3, orforglipron vs semaglutide tablets (Rybelsus) produced a larger fall in HbA1c and more weight loss (details below).
Retatrutide vs orforglipron: how the pill compares with injections
In shortThe pill is the most convenient and the least powerful; retatrutide is the strongest so far.
Top arm, counting everyone who started (treatment-regimen estimand). TRIUMPH-1, SURMOUNT-1, STEP 1, OASIS 4, ATTAIN-1. Separate trials.
Tap a drug to see what it is and where it stands
Once-daily small-molecule pill (Foundayo). GLP-1 receptor only, biased towards cAMP signalling. 11.2% weight loss at 72 weeks counting everyone who started. Licensed in the US and UK in 2026.
Oral semaglutide, a peptide tablet with an absorption enhancer and fasting rules. GLP-1 only. 13.6% at 64 weeks in OASIS 4. MHRA authorised 11 June 2026.
Weekly peptide injection (Wegovy). GLP-1 only. 14.9% at 68 weeks in STEP 1. Proven to cut heart attacks and strokes in people with heart disease.
Weekly peptide injection (Mounjaro). GLP-1 plus . 20.9% at 72 weeks in SURMOUNT-1. Beat semaglutide head to head in SURMOUNT-5 (20.2% against 13.7%).
Weekly peptide injection, still experimental. GLP-1, GIP and glucagon. 25.0% at 80 weeks in TRIUMPH-1 counting everyone (28.3% on treatment). Lilly plans a US filing in early 2027. Not approved anywhere; ALTA supplies it only as a research reagent.
Lilly, Novo Nordisk and trial publications to November 2026.
Using the counting method that includes everyone who started each trial, average weight loss on the top arm was: orforglipron 11.2% at 72 weeks (ATTAIN-1), the Wegovy pill 13.6% at 64 weeks (OASIS 4), semaglutide injection 14.9% at 68 weeks (STEP 1), tirzepatide 20.9% at 72 weeks (SURMOUNT-1) and retatrutide 25.0% at 80 weeks (TRIUMPH-1). None of these are head-to-head comparisons, but the pattern is clear: each extra hormone receptor has added weight loss, and the single-receptor pills sit at the bottom.
That is the trade-off in orforglipron vs tirzepatide or retatrutide: an oral GLP-1 built for convenience and scale against injections that add GIP (tirzepatide) or GIP and glucagon (retatrutide, still experimental, US filing planned for early 2027). Our retatrutide vs tirzepatide comparison and the retatrutide phase 3 trials guide cover the injectable side in depth.
Where orforglipron fits with ALTA's research peptides
In shortWe can't sell it. For lab work, retatrutide is the triple-agonist reference.
| Orforglipron | Retatrutide | |
|---|---|---|
| Molecule | Non-peptide small molecule | 39-amino-acid peptide |
| Receptors | GLP-1 | GLP-1, GIP, glucagon |
| Status | Licensed medicine (UK, US) | Phase 3 complete; not approved |
| Sold by ALTA | No, prescription only | Research vial £109.99; pen £139.99 |
ALTA prices November 2026. Research reagents for in-vitro use only.
ALTA PEPTIDES does not stock orforglipron, and cannot: it is a licensed prescription medicine, and there is no legitimate research-grade version of a branded tablet. Anything sold online as orforglipron outside a pharmacy should be treated as unverified.
For laboratory research on incretin-receptor pharmacology, the natural reference point sits at the other end of the spectrum. Orforglipron is a non-peptide that switches on one receptor and favours one signalling route. Retatrutide is a 39-amino-acid peptide that switches on three receptors, GLP-1, GIP and glucagon, and it is the triple agonist that newer single- and dual-receptor compounds are measured against. Set against orforglipron's published data, retatrutide lets a lab ask how much comes from receptor breadth and how much from signalling style.
We hold retatrutide research vials (40 mg, £109.99) and a sealed retatrutide pen (£139.99), each retatrutide lot matched to a published certificate. They are reagents for laboratory research only, not medicines and not for human use. See our retatrutide explainer and how to read a certificate of analysis for what to check on any retatrutide lot.
Everything above is the quick version. The sections below go deeper.
How a small molecule switches on a peptide receptor
In shortThe structural biology behind the pill.
Kawai et al., PNAS 2020; Coskun et al., Cell Metab 2022; Pfizer, 14 April 2025.
The GLP-1 receptor is a class B G-protein-coupled receptor. Its natural key is a 30-amino-acid hormone that grips both the receptor's large outer domain and its core, and for years that made it look out of reach for small drugs. In 2020, Chugai and Lilly scientists, working with Nobel laureate Brian Kobilka, published a cryo-electron microscopy structure in PNAS showing LY3502970 bound in a pocket in the upper part of the receptor's helical bundle, held by the outer domain, an extracellular loop and several transmembrane helices.
Laboratory studies describe orforglipron as a potent partial agonist that favours the cAMP signal while recruiting little beta-arrestin, the protein that pulls activated receptors back into the cell. This is called biased agonism; whether it changes weight loss or tolerability in people is not established.
Orforglipron in type 2 diabetes: the ACHIEVE trials
In shortThe diabetes trials, including a win over oral semaglutide.
| Orforglipron 36 mg | Oral semaglutide 14 mg | |
|---|---|---|
| HbA1c fall (from 8.3%) | 2.2 points | 1.4 points |
| Weight loss | 9.2% | 5.3% |
| Stopped due to side effects | 9.7% | 4.9% |
Lilly ACHIEVE-3 results, efficacy estimand. 1,698 adults on metformin, open-label.
ACHIEVE-1 (NEJM, June 2025) tested orforglipron alone in 559 adults with type 2 diabetes for 40 weeks. From a starting HbA1c of 8.0%, the three arms lowered it by about 1.3 to 1.6 points against 0.1 on placebo, and the top arm lost 7.9% of body weight, still falling at the end. Up to 76% reached the HbA1c target below 7%.
ACHIEVE-3 was open-label and head-to-head: 1,698 adults on metformin, 52 weeks, orforglipron 12 and 36 mg against oral semaglutide 7 and 14 mg. The 36 mg arm lowered HbA1c by 2.2 points against 1.4 for oral semaglutide 14 mg, and weight by 9.2% against 5.3%. More people stopped because of side effects on orforglipron (8.7% and 9.7%) than on oral semaglutide (4.5% and 4.9%). Lilly now labels its marketed tablet strengths differently from the trial arm names, so the numbers on packs do not match the trial arms.
Foundayo tablet strengths: what the Foundayo pill contains and how the label says it is taken
Foundayo is a once-daily weight loss tablet that contains the active ingredient orforglipron, a GLP-1 receptor agonist for obesity and overweight. The pill contains no peptide. The US prescribing information lists six tablet strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg. Under the MHRA authorisation, treatment begins at the 0.8 mg strength and steps up through each level, with a minimum of one month at each dose of Foundayo. The US label sets 17.2 mg once daily as the maximum.
These numbers differ from the ATTAIN trial arms because the trials used an investigational formulation. The US label presents the trial data as "equivalent dosages" of the marketed tablet.
Foundayo is taken by mouth once a day. The MHRA states that Foundayo can be taken at any time of day with no food or water restrictions, and the US label says with or without food. That is the practical difference from the Wegovy tablet, which is oral semaglutide.
Foundayo side effects: the serious side effects and warnings on the label
The trial rates for nausea and the other digestive effects are in the table above. Beyond those, the US prescribing information lists the serious side effects known for this class. It warns that Foundayo may cause acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from fluid loss, gallbladder disease and serious allergic reactions. In the two weight management trials, severe gastrointestinal reactions were reported in approximately 3% of patients on orforglipron against 1% on placebo, and gallstones in 1% against 0.7%.
The boxed warning on thyroid C-cell tumours comes from the class. The label states that orforglipron did not produce tumours in rodents, and that the human relevance of the rodent findings has not been determined.
Two points concern other medicines. The label advises women who take Foundayo with an oral contraceptive to switch to a non-oral method, or add a barrier method, for 30 days after starting Foundayo and for 30 days after each dose increase. It also says use with another GLP-1 receptor agonist is not recommended.
Foundayo in the UK in November 2026: private prescription, NICE and the NHS
The UK is the first country in Europe to authorise this oral pill. The MHRA approved Foundayo for weight loss and weight maintenance in adults with a BMI of 30 or above, or of 27 to 30 with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The UK licence also covers type 2 diabetes. The US prescribing information, revised in July 2026, covers weight management only.
Although approved for use in the UK, Foundayo is available on private prescription only, from registered pharmacies. NICE is appraising orforglipron as a weight loss treatment for overweight and obesity. Its project page lists a second committee meeting on 10 November 2026 and an expected publication date of 27 January 2027. Our GLP-1 receptor agonists explainer sets the tablet beside the injections.
Sources
- Wharton S, et al. Orforglipron for obesity (ATTAIN-1). New England Journal of Medicine, 16 September 2025; and Eli Lilly press release on the complete ATTAIN-1 results, same date.
- Eli Lilly. Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy (ATTAIN-MAINTAIN). Press release, 18 December 2025.
- ATTAIN-2: orforglipron in adults with obesity and type 2 diabetes. The Lancet, published online 20 November 2025.
- Rosenstock J, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). New England Journal of Medicine, June 2025.
- Eli Lilly. ACHIEVE-3 topline results: orforglipron versus oral semaglutide in type 2 diabetes. Press release, September 2025; reported by HCPLive, 18 September 2025.
- MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK press release, 10 August 2026.
- Phil Taylor. UK is first European country to approve Lilly's Foundayo. pharmaphorum, 11 August 2026.
- Consultant360. FDA approves orforglipron (Foundayo). April 2026. Medino. Foundayo price UK: cheapest providers compared. 25 August 2026.
- Kawai T, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. PNAS 2020;117(47):29959-29967.
- Wharton S, et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine 2025.
- Novo Nordisk. Wegovy pill approved in the US as first oral GLP-1 for weight management. Press release, 22 December 2025.
- Pfizer. Pfizer provides update on GLP-1-RA clinical development program (danuglipron discontinued). Press release, 14 April 2025.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021;384:989-1002. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022;387:205-216.
- Eli Lilly. Retatrutide TRIUMPH-1 results. Press releases, 21 May and 6 June 2026.
Questions people ask
What is orforglipron?
Orforglipron is a once-daily GLP-1 receptor agonist pill made by Eli Lilly and sold as Foundayo. Unlike semaglutide or tirzepatide it is not a peptide but a small synthetic molecule, so it survives digestion and needs no fasting rules. It is licensed for weight management and, in the UK, type 2 diabetes.
How much weight do people lose on orforglipron?
In ATTAIN-1, adults without diabetes on the top 36 mg arm lost 12.4% of their body weight on average after 72 weeks, against 0.9% on placebo. Counting everyone who started, including those who stopped, it was 11.2% against 2.1%. People with type 2 diabetes lost less, 10.5% in ATTAIN-2.
Is orforglipron approved in the UK?
Yes. The MHRA authorised orforglipron (Foundayo) on 10 August 2026 for weight management and for type 2 diabetes, the first approval in Europe. It is prescription-only and not yet available on the NHS while NICE completes its appraisal.
What is the Foundayo price in the UK?
Lilly has not published an official UK list price. A comparison of UK online pharmacies by Medino in late August 2026 found private prices of roughly £99 to £199 a month depending on strength. Prices change, and some quotes include a consultation.
Is the Wegovy pill UK licensed too?
Yes. The MHRA authorised the Wegovy pill, oral semaglutide, for weight management on 11 June 2026, two months before orforglipron. It is a peptide tablet with fasting rules; orforglipron is a non-peptide without them.
Is orforglipron better than semaglutide?
For weight loss, no, on the published numbers. Orforglipron gave 11.2% at 72 weeks in ATTAIN-1, while semaglutide injections gave 14.9% at 68 weeks in STEP 1 and the Wegovy pill 13.6% at 64 weeks in OASIS 4, all counting everyone who started. In type 2 diabetes, orforglipron beat the lower-strength oral semaglutide (Rybelsus) on HbA1c and weight in the head-to-head ACHIEVE-3 trial.
Retatrutide vs orforglipron: which causes more weight loss?
Retatrutide, by a wide margin on the published numbers: 25.0% at 80 weeks in TRIUMPH-1 against 11.2% at 72 weeks for orforglipron in ATTAIN-1, counting everyone who started. They are very different drugs: retatrutide is an injected peptide acting on three hormone receptors and is still experimental, while orforglipron is an approved pill acting on one.
What are the side effects of orforglipron?
Mainly digestive: nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain, mostly mild to moderate and most common while the amount was being stepped up. In ATTAIN-1, nausea affected 33.7% on the top arm against 10.4% on placebo. Lilly reported no liver safety signal.
When will orforglipron be available in the UK?
It already is, on private prescription. The MHRA authorised the orforglipron weight loss pill, sold as Foundayo, on 10 August 2026, and UK pharmacies supply it privately, with the orforglipron price set by each pharmacy. It is not yet available on the NHS while NICE completes its appraisal.
Orforglipron FDA approval status 2026: is it approved?
Yes. The US FDA approved orforglipron for chronic weight management on 1 April 2026, under the brand name Foundayo. The UK's MHRA authorised the same orforglipron tablet on 10 August 2026 for weight management and type 2 diabetes, the first approval in Europe.
How does Foundayo work?
Foundayo contains orforglipron, a GLP-1 receptor agonist. The MHRA describes it as mimicking GLP-1, a hormone released after eating, and acting on the areas of the brain that regulate appetite, so people feel fuller for longer and have fewer food cravings. In people with type 2 diabetes it also lowers blood sugar when levels are high.
Can Foundayo and Mounjaro or Wegovy be taken together?
The US prescribing information says use of Foundayo with another GLP-1 receptor agonist is not recommended. Wegovy is semaglutide, a GLP-1 receptor agonist. Mounjaro is tirzepatide, which acts on GLP-1 and GIP receptors. In the ATTAIN-MAINTAIN trial, people switched from an injection to the pill and did not take both.
Is the Foundayo pill for weight loss available on the NHS?
Not yet. The MHRA said at authorisation that the tablet is not currently available via the NHS and that NHS use depends on an evaluation by NICE. NICE's project page gives an expected publication date of 27 January 2027.
Information, not advice. This article summarises published research; nothing here is guidance on human or veterinary use. Products are sold under our research use policy.

